A significant, often overlooked, hurdle in drug development is that therapeutic antibodies bind differently to animal targets than human ones. This discrepancy can force excessively high doses in animal studies, leading to toxicity issues and causing promising drugs to fail before ever reaching human trials.
The company's core technology, AlphaSeq, uses engineered yeast mating as a proxy for protein binding. The rate of mating corresponds to the binding affinity of proteins on the cell surfaces. By sequencing the resulting cells, the company can count genetic barcodes to quantitatively measure millions of protein-protein interactions at once.
The cost to generate the volume of protein affinity data from a single multi-week A-AlphaBio experiment using standard methods like surface plasmon resonance (SPR) would be an economically unfeasible $100-$500 million. This staggering cost difference illustrates the fundamental barrier that new high-throughput platforms are designed to overcome.
Contrary to the popular belief that antibody development is a bespoke craft, modern methods enable a reproducible, systematic engineering process. This allows for predictable creation of antibodies with specific properties, such as matching affinity for human and animal targets, a feat once considered a "flight of fancy."
While AI promises to design therapeutics computationally, it doesn't eliminate the need for physical lab work. Even if future models require no training data, their predicted outputs must be experimentally validated. This ensures a continuous, inescapable cycle where high-throughput data generation remains critical for progress.
Traditional antibody optimization is a slow, iterative process of improving one property at a time, taking 1-3 years. By using high-throughput data to train machine learning models, companies like A-AlphaBio can now simultaneously optimize for multiple characteristics like affinity, stability, and developability in a single three-month process.